Immune tolerance

Sonoma Biotherapeutics to Present Preclinical Data from Novel Treg Cell Therapy for Rheumatoid Arthritis at American College of Rheumatology Convergence 2022

Retrieved on: 
Thursday, November 10, 2022
Health, Clinical Trials, Research, Pharmaceutical, Science, Biotechnology, Rheumatoid arthritis, Protein, Division, University of California, San Francisco, Biology, Immune tolerance, Synovial fluid, American College of Rheumatology, Joint, Inflammation, Autoimmunity, Pennsylvania Convention Center, University, Patient, Immune system, Northwest Biotherapeutics, ACR, RA, Antigen, American College, Pharmaceutical industry, Vaccine, Regulatory T cell, Rheumatology

Sonoma Biotherapeutics, Inc., a clinical-stage biotechnology company developing engineered regulatory T cell (Treg) therapies for autoimmune and inflammatory diseases, will be presenting key data at the American College of Rheumatology (ACR) Convergence 2022 Scientific Sessions highlighting preclinical data from the companys autologous Treg therapy for the treatment of rheumatoid arthritis (RA).

Key Points: 
  • Sonoma Biotherapeutics, Inc., a clinical-stage biotechnology company developing engineered regulatory T cell (Treg) therapies for autoimmune and inflammatory diseases, will be presenting key data at the American College of Rheumatology (ACR) Convergence 2022 Scientific Sessions highlighting preclinical data from the companys autologous Treg therapy for the treatment of rheumatoid arthritis (RA).
  • Citrullinated proteins are neo-self-antigens that accumulate in autoimmune and inflammatory diseases and are known to lead to pathogenic autoantibodies in RA.
  • Sonoma Biotherapeutics is a clinical-stage biotechnology company developing engineered regulatory T cell (Treg) therapies to treat serious autoimmune and inflammatory diseases by restoring balance to the immune system.
  • Founded by pioneers in Treg biology and cell therapy, the company is employing proprietary platform technologies and approaches to develop a new generation of targeted and durable Treg cell therapies.

SQZ Biotechnologies Reports Third Quarter 2022 Financial Results and Recent Portfolio Updates

Retrieved on: 
Wednesday, November 9, 2022
Oncology, Health, Infectious Diseases, Clinical Trials, Pharmaceutical, Biotechnology, Private Securities Litigation Reform Act, Engineering, Risk, NYSE, Translational research, Immune tolerance, Cell, Board, SQZ, Doctor of Philosophy, Annual report, Degenerative disease, SVP, U.S. Securities and Exchange Commission, Infection, Confidentiality, Shuping Yang commencement speech controversy, Autoimmunity, CSO, Cancer, AAC, Research, Patient, CEO, Therapy, VP, Anticipation, COVID-19, POC, Pharmaceutical industry, Management

SQZ Biotechnologies (NYSE: SQZ), focused on unlocking the full potential of cell therapies for multiple therapeutic areas, today reported third quarter 2022 financial results and recent portfolio updates.

Key Points: 
  • SQZ Biotechnologies (NYSE: SQZ), focused on unlocking the full potential of cell therapies for multiple therapeutic areas, today reported third quarter 2022 financial results and recent portfolio updates.
  • I am proud of the SQZ team's accomplishments this quarter, including our publication showcasing the AAC platform, advancing our autoimmune preclinical work, and progress made developing our integrated point-of-care manufacturing system, said Armon Sharei, Ph.D., CEO and Founder at SQZ Biotechnologies.
  • As we head into the final stretches of the year, we look forward to sharing the latest available clinical data from our three oncology trials.
  • Actual results could differ from those projected in any forward-looking statements due to several risk factors.

OncoC4 to Present Positive Data from Ongoing Phase 1/2 PRESERVE-001 Trial of ONC-392 in Combination with pembrolizumab at SITC 2022

Retrieved on: 
Monday, November 7, 2022
ORR, DLT, Immune tolerance, Neoplasm, RECIST, Tumor microenvironment, Nivolumab, Boston Convention and Exhibition Center, PH, GLOBE, Adenoid cystic carcinoma, FDA, Safety, Pharmacokinetics, NSCLC, University, Cervical cancer, Triple-negative breast cancer, Ipilimumab, Immunotherapy, Partial-response maximum-likelihood, CEO, Ira Pastan, Huntsman Cancer Institute, PR, DCR, Doctor of Philosophy, Pembrolizumab, PD, Histology, Therapeutic index, Toxicity, Degenerative disease, Melanoma, SD, Society, SITC, Patient, Convention center, Cancer, Vaccine, Pharmaceutical industry, Palladium, Medical imaging, Aluminium

The data will be featured in an oral presentation at the Society for Immunotherapy of Cancers (SITC) 37th annual meeting.

Key Points: 
  • The data will be featured in an oral presentation at the Society for Immunotherapy of Cancers (SITC) 37th annual meeting.
  • The recommended Phase 2 dose has been established at 6 mg/kg of ONC-392 in combination with 200 mg of pembrolizumab.
  • We are excited to share positive, initial results from the combination therapy portion of the PRESERVE-001 trial at the prestigious annual SITC meeting, said Yang Liu, CEO of OncoC4, Inc.
  • In addition, OncoC4 has a pipeline of first-in-class preclinical products focusing on the CD24-Siglecs cancer immune evasion pathway.

23andMe Trials-in-Progress Poster Details Expansion Cohorts for 23ME-00610, an Investigational Antibody Targeting CD200R1, at The Society for Immunotherapy of Cancer’s (SITC) 2022 Annual Meeting

Retrieved on: 
Monday, November 7, 2022
Doctor of Philosophy, Patient, Neoplasm, Immune tolerance, Research, Sumathi Best Television Current Reporting Award, MSI-H, Therapy, Growth, Maintenance, SAN, PLOS, PLOS Genetics, Genetics, GLOBE, Squamous cell carcinoma, Safety, Pharmacokinetics, Securities Exchange Act of 1934, Poster, Terminology, Nature Genetics, Immunotherapy, Securities Act of 1933, 23andMe, Annual general meeting, Annual report, U.S. Securities and Exchange Commission, Cancer, Genome, Helios Techno Holding Co., Ltd., Security (finance), Society, CD200, SITC, MD, Nature, Myelocyte, Primary peritoneal carcinoma, Pharmaceutical industry, Vaccine, CD200R1

A cohort of adolescents with locally advanced unresectable, or metastatic solid malignancies will also be enrolled.

Key Points: 
  • A cohort of adolescents with locally advanced unresectable, or metastatic solid malignancies will also be enrolled.
  • 23andMe has more than 13 million genotyped customers, over 80% of whom consent to participate in research.
  • 23andMe scientists study the aggregate, de-identified genetics of these participants, alongside more than 4 billion self-reported health data points.
  • Title: A Phase 1 Dose Escalation and Expansion Study of the anti-CD200R1 Antibody 23ME-00610 in Patients with Advanced Solid Malignancies.

Vaccitech Provides Update on Ongoing VTP-300 Phase 1b/2a Trial Showing Sustained Reductions of HBsAg in Patients with Chronic Hepatitis B

Retrieved on: 
Monday, November 7, 2022
University of Ulsan College of Medicine, Liver disease, Patient, Immune tolerance, Ulsan College, IB Group 2 subjects, Liver, Nivolumab, GLOBE, Asian Liver Center, Modified vaccinia Ankara, Safety, Department, Poster, Group 3, Group 1, University, AASLD, Group 2, HBV, MVA, Vaccine, NASDAQ, Hepatitis, Infection, Disease, Antigen, Degenerative disease, American Association, Association, Cancer, Group 4, OXFORD, Pharmaceutical industry, Vaccitech, HBsAg

OXFORD, United Kingdom, Nov. 07, 2022 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ: VACC), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapies and vaccines for the treatment and prevention of infectious diseases, cancer, and autoimmune diseases, today announced an update to the interim analysis of safety and efficacy data from its HBV002 trial (NCT04778904). The data will be presented as a poster at the 2022 American Association for the Study of Liver Disease (AASLD) - The Liver Meeting® by Dr. Young-Suk Lim, Professor of the Department of Gastroenterology and the Liver Center, Asian Medical Center, University of Ulsan College of Medicine, Korea.

Key Points: 
  • VTP-300 induced sustained reductions of hepatitis B surface antigen in people with chronic hepatitis B during ongoing, fully enrolled Phase 1b/2a trial.
  • Vaccitechs updated interim analysis includes data from the fully-enrolled trial of 55 patients with chronic hepatitis B (HBV) with at least three months of follow-up.
  • It shows that VTP-300 induced meaningful, sustained reductions of HBV surface antigen (HBsAg) in people with chronic HBV.
  • Enrollment in the HBV002 trial is complete, with a final update expected early in the second quarter of 2023.

Genenta Update at SITC22 Indicates Potential for Anti-Tumor Immune System Reset after Temferon™ Treatment in Glioblastoma Patients

Retrieved on: 
Monday, November 7, 2022
NEW, Stem cell, Neoplasm, Immune tolerance, Therapy, Tumor microenvironment, Glioblastoma, Mirna, GLOBE, Mouse, Private Securities Litigation Reform Act, TME, Poster, Immunotherapy, HSC, CEO, Interferon, Annual report, U.S. Securities and Exchange Commission, Forward-looking statement, Immune system, Security (finance), Toxicity, Monocyte, Society, SITC, Patient, Society for Immunotherapy of Cancer, Medical imaging, Vaccine

MILAN, Italy and NEW YORK, Nov. 07, 2022 (GLOBE NEWSWIRE) -- Genenta Science (Nasdaq: GNTA) (“Genenta” or the “Company”), a clinical-stage immuno-oncology company developing a cell-based platform harnessing the power of hematopoietic stem cells (HSC) to provide durable and safe treatments for solid tumors, will present at the 2022 annual meeting of the Society for Immunotherapy of Cancer (SITC) data showing signs of Temferon-induced changes in the tumor microenvironment of patients affected by glioblastoma multiforme and activation of the immune system that may result in the inhibition of tumor growth.

Key Points: 
  • Single cell sequencing analyses of the TME unveiled a pro-inflammatory reprogramming of the myeloid and T cells compartment of Temferon-treated patients.
  • This pro-inflammatory pattern was associated in preclinical studies with tumor responses and in a fraction of mice with tumor eradication.
  • When you show that Temferon can re-tune the immune status of the tumor and its immediate surroundings under such challenging conditions, many treatment possibilities emerge.
  • Forward-looking statements contained in this announcement are made as of this date, and Genenta undertakes no duty to update such information except as required under applicable law.

Selecta Biosciences to Participate at the Guggenheim Healthcare Talks | 4th Annual Immunology & Neurology Day

Retrieved on: 
Monday, November 7, 2022
GLOBE, Immune tolerance, Company, Degenerative disease, Biotechnology, NASDAQ, Vaccine, Greater Boston

To schedule a meeting with the Company, please contact your Guggenheim representative.

Key Points: 
  • To schedule a meeting with the Company, please contact your Guggenheim representative.
  • Selecta Biosciences Inc. (NASDAQ: SELB) is a clinical stage biotechnology company leveraging its ImmTOR platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses.
  • Selecta has several proprietary and partnered programs in its pipeline focused on enzyme therapies, gene therapies, and autoimmune diseases.
  • Selecta Biosciences is headquartered in the Greater Boston area.

Talaris Therapeutics Presents Data on Mechanisms of FCR001 Activity to Induce Immune Tolerance

Retrieved on: 
Monday, November 7, 2022
RNA, Company, Immune tolerance, Private Securities Litigation Reform Act, Research, RNA transfection, Society, GLOBE, Safety, Therapy, Nasdaq, Degenerative disease, Annual general meeting, ASN, U.S. Securities and Exchange Commission, Risk, American Society of Nephrology, Immune reconstitution inflammatory syndrome, Observation, Security (finance), Facilitated communication, Patient, Vaccine, Pharmaceutical industry, Talari Networks

The first presentation reported on transcriptional changes following successful tolerization with FCR001.

Key Points: 
  • The first presentation reported on transcriptional changes following successful tolerization with FCR001.
  • We are pleased to present these new analyses that shed light on how FCR001 treatment may modulate the immune landscape to induce durable immune tolerance, said Nancy Krieger, M.D., Chief Medical Officer of Talaris.
  • Talaris Therapeutics, Inc. is a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of care in solid organ transplantation and severe immune and blood disorders.
  • Talaris maintains corporate offices in Boston, MA, its cell processing facility in Louisville, KY, and additional research operations in Houston, TX.

Selecta Biosciences Reports Third Quarter 2022 Financial Results and Provides Business Update

Retrieved on: 
Thursday, November 3, 2022
Immune tolerance, Pandemic, DMD, Sarepta, Investor, Research, Partnership, Immunoglobulin G, Annual report, U.S. Securities and Exchange Commission, Clinical trial, Autoimmune disease, Disease, MMA, Muscular dystrophy, Administration, Primary biliary cholangitis, Anticipation, Company, GLOBE, PBC, Intellectual property, IND, Degenerative disease, Patient, Autoimmunity, Preclinical development, ESGCT, Biotechnology, Private Securities Litigation Reform Act, Gout, European Society of Gene and Cell Therapy, Intention, Review, LGMD, Telephone, Re Recher's Will Trusts, Cell, Primary, Conference, Immunoglobulin A, NASDAQ, Glycogen storage disease, Gene, Development, Duchenne muscular dystrophy, Achievement, AAV, Immunity, Cryptocurrency, Pharmaceutical industry, Vaccine, IgA nephropathy, Selecta, Greater Boston

Selecta continues to work with its partners to develop a next generation IL-2 molecule to combine with ImmTOR and still anticipates selecting an IL-2 candidate by year-end 2022.

Key Points: 
  • Selecta continues to work with its partners to develop a next generation IL-2 molecule to combine with ImmTOR and still anticipates selecting an IL-2 candidate by year-end 2022.
  • In Q3 2022, Selecta received a $10 million milestone payment from Sobi following the completion of enrollment of DISSOLVE II in June 2022.
  • Selecta management will host a conference call at 8:30 AM ET today to provide a business update and review the companys third quarter 2022 financial results.
  • The Company specifically disclaims any intention to update any forward-looking statements included in this press release, except as required by law.

LUMC to Fund New Clinical Trial of Cynata's Cymerus™ MSCs in Kidney Transplantation

Retrieved on: 
Friday, November 4, 2022
Holm–Bonferroni method, Subclinical infection, Immune tolerance, Ageing, Asthma, Infection, Chronic kidney disease, DFU, Idiopathic pulmonary fibrosis, Pakistan Library Automation Group, Ethics, Internal medicine, Cytokine release syndrome, FDA, Safety, Incidence, ASX, Potency (pharmacology), Sepsis, Ulcer, Therapy, Leiden University Medical Center, Stem cell, Graft-versus-host disease, Acute respiratory distress syndrome, Transplant, Microsoft, Kidney transplantation, Regenerative medicine, US, MCA, Clinical trial, LUMC, MSC, Risk, Efficacy, Kidney, Survival, Patient, Osteoarthritis, Cancer, Department, Dialysis, Pharmaceutical industry, Dentistry

MELBOURNE, Australia, Nov. 4, 2022 /PRNewswire/ -- Cynata Therapeutics Limited (ASX: "CYP" or "Cynata"), a clinical-stage biotechnology company specialising in cell therapeutics, is delighted to announce that the LUMC is funding an important clinical trial to investigate Cynata's Cymerus™ MSCs as a treatment for renal graft rejection and to potentially reduce the requirement for anti-rejection drugs.

Key Points: 
  • Kidney transplantation is life-saving in patients with chronic renal failure and frees the patient from the need for dialysis.
  • The clinical trial, entitled the "Safety and Efficacy of iPSC-derived Mesenchymal Stromal Cell Therapy in Renal Transplant Recipients - the Nereid Study", will be led by Prof.
  • "This exciting new collaboration follows very promising clinical trial data with MSCs published by Professor Rabelink[1] and our own published pre-clinical data[2] in organ transplant rejection.
  • The consistency and potency of Cynata's unique iPSC-derived Cymerus MSCs make them an ideal candidate for this clinical trial."